Clinical Trial Update: Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

View source ↗

Summary

A clinical trial evaluating cenicriviroc plus FTC/TDF for HIV infection and its effect on cardiovascular risk factors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Cenicriviroc (cenicriviroc)
• Emtricitabine/Tenofovir disoproxil fumarate (emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: University of California, San Francisco | Conditions: HIV Infection | Status: TERMINATED